26 completed. 26 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 26 |
| Phase 2 | 1 | Completed 1 |
Follow Tolerability: new trials by email Literature Review of Tolerability trials Research Report on Tolerability
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of Y-3 in US Healthy Volunteers. Y-3 for injection, Placebo - Safety, Tolerability | Phase 1 | Completed | Neurodawn Pharmaceutical Co., Ltd. | 20 | 2025-02-04 | 2025-12-18 |
| SB17170 Phase1 Trial in Healthy Volunteer SB17170, Placebo - Safety Issues, Tolerability | Phase 1 | Completed | SPARK Biopharma | 64 | 2023-05-24 | 2024-03-21 |
| Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers RHN-001 (one tablet 750mg), RHN-001 (750mg * 2 Tablets) - Safety, Tolerability | Phase 1 | Completed | RH Nanopharmaceuticals | 64 | 2023-03-09 | 2023-05-06 |
| Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers 5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo - Pharmacokinetics, Safety | Phase 1 | Completed | Usona Institute | 54 | 2022-12-27 | 2023-11-30 |
| Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam Linaprazan glurate, Drug drug interaction (DDI) - Clarithromycin (Part I), Drug drug interaction (DDI) - Midazolam (Part 2) - Safety Issues, Pharmacokinetics | Phase 1 | Completed | Cinclus Pharma Holding AB | 35 | 2022-11-27 | 2025-01-03 |
| Clinical Trial on Pharmacokinetics and Tolerability of AP707 AP707 - Pharmacokinetics, Tolerability | Phase 1 | Completed | CannaXan GmbH | 12 | 2022-03-02 | 2022-07-27 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants AZD7503, Placebo - Safety, Tolerability | Phase 1 | Completed | AstraZeneca | 56 | 2021-12-06 | 2025-02-19 |
| Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors IPG7236 - Safety Issues, Tolerability | Phase 1 / Phase 2 | Completed | Nanjing Immunophage Biotech Co., Ltd | 34 | 2021-11-15 | 2026-07-08 |
| Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects AM1476, Placebo - Safety, Tolerability | Phase 1 | Completed | AnaMar AB | 97 | 2020-12-16 | 2024-08-02 |
| Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ Bepotastine Besilate - Safety, Tolerability | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 22 | 2020-09-24 | 2025-07-16 |
| Clinical Trial on Pharmacokinetic and Tolerability of AP701 AP701 - Pharmacokinetic, Tolerability | Phase 1 | Completed | CannaXan GmbH | 15 | 2020-01-11 | 2021-03-10 |
| Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers Placebo, Foralumab Nasal - Safety, Tolerability | Phase 1 | Completed | Tiziana Life Sciences LTD | 27 | 2018-11-12 | 2025-03-17 |
| A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567. AZD9567 Monohydrat, Placebo oral suspension/ Placebo capsule, Prednisolone - Safety, Tolerability | Phase 1 | Completed | AstraZeneca | 72 | 2015-11-18 | 2018-10-04 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males AZD9977, oral suspension, Placebo, oral suspension, AZD9977, oral solution - Safety, Tolerability | Phase 1 | Completed | AstraZeneca | 196 | 2015-07-01 | 2017-04-28 |
| Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants. DS-1971, placebo - Safety, Tolerability | Phase 1 | Completed | Daiichi Sankyo | 64 | 2014-03-01 | 2018-12-24 |
| Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects Dexanabinol Dose Level 1, Dexanabinol Dose Level 2, Dexanabinol Dose Level 3 - Safety, Tolerability | Phase 1 | Completed | e-Therapeutics PLC | 40 | 2014-01-01 | 2016-05-23 |
| A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans ASP7962, Placebo - Safety, Tolerability | Phase 1 | Completed | Astellas Pharma Europe B.V. | 48 | 2013-11-01 | 2014-07-11 |
| A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal Androxal, Placebo - Pharmacokinetics, Tolerability | Phase 1 | Completed | Repros Therapeutics Inc. | 9 | 2013-10-01 | 2014-08-11 |
| Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects selexipag, placebo for selexipag, moxifloxacin - Cardiodynamics, Safety | Phase 1 | Completed | Actelion | 159 | 2012-06-01 | 2014-08-01 |
| Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206 ACT-462206 5 mg, ACT-462206 25 mg, ACT-462206 100mg - Safety, Tolerability | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 56 | 2011-11-01 | 2018-07-10 |
Showing 20 of 26. Sign in to see all of them.
Marijuana Abuse (2) · Neoplasms (2) · Alzheimer Disease (1) · Arthritis, Rheumatoid (1) · Dyskinesias (1) · Parkinson Disease (1) · Respiratory Aspiration (1) · Stroke (1)
Brain Diseases (3) · Central Nervous System Diseases (3) · Mental Disorders (3) · Nervous System Diseases (3) · Chemically-Induced Disorders (2) · Neurodegenerative Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Substance-Related Disorders (2) · Arthritis (1) · Autoimmune Diseases (1) · Basal Ganglia Diseases (1) · Cardiovascular Diseases (1) · Cerebrovascular Disorders (1) · Connective Tissue Diseases (1) · Dementia (1)
ACT-462206 (1) · AZD3839 (1) · AZD9819 (1) · AZD9977 (1) · Clarithromycin (1) · Didanosine (1) · Dronabinol (1) · Drug Interactions (1) · Enclomiphene (1) · Injections (1) · Methoxydimethyltryptamines (1) · Midazolam (1) · Moxifloxacin (1) · Prednisolone (1) · Sodium Chloride (1)
AstraZeneca (7) · CannaXan GmbH (2) · Actelion (1) · AnaMar AB (1) · Astellas Pharma Europe B.V. (1) · Cinclus Pharma Holding AB (1) · Daiichi Sankyo (1) · Idorsia Pharmaceuticals Ltd. (1) · Laboratorios Sophia S.A de C.V. (1) · Nanjing Immunophage Biotech Co., Ltd (1) · NeuroSearch A/S (1) · Neurodawn Pharmaceutical Co., Ltd. (1) · RH Nanopharmaceuticals (1) · Repros Therapeutics Inc. (1) · SPARK Biopharma (1)
United States (9) · United Kingdom (7) · Germany (4) · China (2) · Mexico (1) · Netherlands (1) · Pakistan (1) · South Korea (1) · Sweden (1)
Billings W Billings, MD (1) · Brendan Smyth (1) · Colleen Jensen (1) · David Mathews, MD (1) · Dr Darren Wilbraham, MBBS DCPSA (1) · Dr Paul Bjornsson (1) · Izhar Hasan, MD, PhD (1) · Joseph S Podolski (1) · Karin Palm (1) · Li Zhang, Professor (1) · Matthias Hoch, PhD (1) · Muhammad Raza Shah, PhD (1) · Muna Albayaty, Dr. (1) · Petra Baecker, MD (1)
PMID 12750546, PMID 31601801, PMID 32087818, PMID 33148815, PMID 34487721, PMID 37185136, PMID 37832977, PMID 38258274
2015 (2)